Compare GMM & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GMM | MREO |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | China | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.9M | 52.5M |
| IPO Year | 2022 | 2017 |
| Metric | GMM | MREO |
|---|---|---|
| Price | $1.52 | $0.32 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 90.0K | ★ 1.3M |
| Earning Date | 01-09-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $500,000.00 |
| Revenue This Year | N/A | $6,000.20 |
| Revenue Next Year | N/A | $34.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.94 | $0.20 |
| 52 Week High | $3.39 | $2.94 |
| Indicator | GMM | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 66.82 | 37.87 |
| Support Level | $1.41 | $0.32 |
| Resistance Level | $1.62 | $0.42 |
| Average True Range (ATR) | 0.13 | 0.03 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 96.08 | 21.66 |
Global Mofy AI Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital asset development for the metaverse industry. The Company leverages its proprietary Mofy Lab technology platform, which integrates three-dimensional (3D) reconstruction technology and artificial intelligence (AI) interactive technology, to create high-definition virtual versions of physical world objects, including humans, animals, and scenes. It provides comprehensive technology solutions to support virtual content production for use across movies, television series, animation, advertising, and gaming. The Company operates through Virtual Technology Services, which generates the majority of revenue, and Digital Asset Development and others.
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).